Pain

The selection of available analgesic drugs has improved in recent years; however, standard treatment options for management of chronic cancer pain, post-surgical pain, and neuropathic pain remain less than optimal.

• Up to 70% of cancer patients cannot take oral medications
• 40-50% of cancer patients do not receive adequate pain relief
• Up to 75% of post-operative surgery patients do not receive adequate pain relief
• Opioids and NSAIDS (non-steroidal anti-inflammatory drugs) are associated with adverse effects, such as constipation, respiratory depression, cognitive impairment, and GI bleeding, which limit their use.

In the area of analgesia, Angiochem is developing a promising neurotensin derivative, based on its EPiC technology platform, for the management of moderate to severe post-surgical and cancer pain. > More about ANG2002

Also, Angiochem is in the discovery phase of a new engineered morphine derivative that shows potential for greater efficacy at a lower dose with the resulting benefit of fewer side effects. > More about ANG2010